CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. OVERVIEW OF BIOSIMILARS IN INDIAN MARKET
3.3.1. India an early adopter of biosimilars
3.3.2. Regulation
3.3.3. Clinical trials
3.4. MARKET SHARE ANALYSIS/ TOP PLAYER POSITIONING, 2016
3.5. PORTER’S FIVE FORCES ANALYSIS
3.6. MARKET DYNAMICS
3.6.1. Drivers
3.6.2. Restraints
3.6.3. Opportunities

CHAPTER 4 INDIA BIOSIMILARS & FOLLOW-ON BIOLOGICS MARKET, BY PRODUCT

4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. ERYTHROPOETIN
4.2.1. Market size and forecast
4.3. GRANULOCYTE-COLONY STIMULATING FACTOR
4.3.1. Market size and forecast
4.4. GROWTH HORMONE
4.4.1. Market size and forecast
4.5. ALFA INTERFERON
4.5.1. Market size and forecast
4.6. BETA INTERFERON
4.6.1. Market size and forecast
4.7. MONOCLONAL ANTIBODY
4.7.1. Market size and forecast
4.8. FOLLITROPIN
4.8.1. Market size and forecast
4.9. OTHERS
4.9.1. Market size and forecast

CHAPTER 5 INDIA BIOSIMILARS & FOLLOW-ON BIOLOGICS MARKET, BY APPLICATION

5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. BLOOD DISORDER
5.2.1. Market size and forecast
5.3. CANCER
5.3.1. Market size and forecast
5.4. CHRONIC AND AUTOIMMUNE DISEASE
5.4.1. Market size and forecast
5.5. GROWTH HORMONE DEFICIENCY
5.5.1. Market size and forecast
5.6. OTHERS
5.6.1. Market size and forecast

CHAPTER 6 INDIA BIOSIMILARS & FOLLOW-ON BIOLOGICS MARKET, BY TYPE OF MANUFACTURING

6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. IN-HOUSE MANUFACTURING
6.2.1. Market size and forecast
6.3. CONTRACT MANUFACTURING ORGANIZATION
6.3.1. Market size and forecast

CHAPTER 7 COMPANY PROFILES

7.1. CADILA PHARMACEUTICALS
7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments
7.2. LUPIN LIMITED
7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments
7.3. TORRENT PHARMACEUTICAL LTD.
7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments
7.4. F. HOFFMANN-LA ROCHE AG
7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments
7.5. SANOFI S.A.
7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments
7.6. WOCKHARDT LIMITED
7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments
7.7. RELIANCE LIFE SCIENCES PRIVATE LIMITED
7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments
7.8. INTAS PHARMACEUTICALS LIMITED
7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments
7.9. DR. REDDY’S LABORATORIES LIMITED
7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments
7.10. BIOCON LIMITED
7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments